Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | PELI1 | Q96FA3 | 2/20 | 0.53 |
| ▸ | AR | P10275 | 2/20 | 0.53 |
| ▸ | CCNC | P24863 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | GALR3 | O60755 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13636232 | 1.00 | ERN1 (0.56) | ERN1MAPTHSP90AA1MAPK1NPSR1 | |
| SCHEMBL30353437 | 1.00 | ERN1 (0.56) | ERN1MAPTHSP90AA1MAPK1NPSR1 | |
| SCHEMBL31238165 | 0.85 | ERN1 (0.60) | ERN1MAPTHSP90AA1MAPK1NPSR1 | |
| SCHEMBL3864314 | 0.84 | ERN1 (0.58) | ERN1MAPTHSP90AA1MAPK1NPSR1 | |
| SCHEMBL3864311 | 0.84 | ERN1 (0.58) | ERN1MAPTHSP90AA1MAPK1NPSR1 | |
| SCHEMBL31289388 | 0.82 | MAPT (0.58) | ERN1MAPTHSP90AA1MAPK1NPSR1 | |
| SCHEMBL11343000 | 0.80 | ERN1 (0.68) | ERN1MAPTHSP90AA1MAPK1NPSR1 | |
| SCHEMBL11343002 | 0.80 | ERN1 (0.68) | ERN1MAPTHSP90AA1MAPK1NPSR1 | |
| Water SCHEMBL11694970 | 0.80 | ALDH1A1 (0.60) | MAPTKMT2AKDM4EGAAPELI1 | |
| SCHEMBL6095141 | 0.80 | PELI1 (0.54) | MAPTKMT2AKDM4EGAAPELI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3490970-B1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | VECTUS BIOSYSTEMS LTD (AU) | 2023-09-13 | — | — | EP | disclosed |
| CN-109661387-B | Composition for treating pulmonary fibrosis | 维克图斯生物系统有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-11401245-B2 | Compositions for the treatment of pulmonary fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2022-08-02 | — | — | US | disclosed |
| US-20210130301-A1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | VECTUS BIOSYSTEMS LIMITED (AU) | 2021-05-06 | — | — | US | disclosed |
| US-10919863-B2 | Compositions for the treatment of pulmonary fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2021-02-16 | — | — | US | disclosed |
| US-20190270712-A1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | VECTUS BIOSYSTEMS LIMITED (AU) | 2019-09-05 | — | — | US | disclosed |
| EP-3490970-A1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | Vectus Biosystems Limited (AU) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018018091-A1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | VECTUS BIOSYSTEMS LIMITED (AU) | 2018-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919863-B2 | Compositions for the treatment of pulmonary fibrosis | ELANE, MMP1, CCL11 | ERN1 4066/4885MAPT 4212/4885HSP90AA1 401/4885 |
| US-11401245-B2 | Compositions for the treatment of pulmonary fibrosis | ELANE, MMP1, CCL11 | ERN1 4066/4885MAPT 4212/4885HSP90AA1 401/4885 |
| US-20190270712-A1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | ELANE, MMP1, CCL11 | ERN1 4066/4885MAPT 4212/4885HSP90AA1 401/4885 |
| US-20210130301-A1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | ELANE, MMP1, CCL11 | ERN1 4066/4885MAPT 4212/4885HSP90AA1 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.